[ad_1]
The American biotechnology company Novavax announced this Friday that it has begun, in the United Kingdom, the final phase of clinical trials of the experimental vaccine to combat the covid-19 pandemic.
The aim of the study is to include 10,000 participants between the ages of 18 and 84, reports AFP.
“Due to the current high level of SARS-CoV-2 transmissions, and given that it is likely to remain high in the UK, we are optimistic that the clinical trial will benefit from rapid recruitment and offer short-term results.” explained. , through a statement, the director of research and development of Novavax, Gregory Glenn.
This is the The world’s 11th experimental vaccine to enter the final phase of clinical trials and involving tens of thousands of participants.
Typically, half of the participants receive a placebo. [agente neutro] and the other half is tested with the vaccine.
In the West, the most advanced projects are those developed by AstraZeneca, partner at the University of Oxford, UK, by Pfizer and Moderna.
There are also Chinese and Russian projects that have already reached the final testing stage.
Novavax. What company is this?
Novavax is one of six companies funded with hundreds of millions of dollars by the United States government and the fifth to enter the final testing phase.
The biotech company received more than $ 1.6 billion (about € 1.3 billion) of US public money to finance the production of 100 million doses.
THE MOST PROMISING VACCINES IN THE FIGHT AGAINST COVID-19
Laboratories around the world are in one race against time to develop a vaccine against the new coronavirus. There are dozens of teams testing various candidate vaccines, some are more advanced and promising.
According to the London School of Hygiene and Tropical Medicine (which has a graph showing the progress of the experiments) there are 243 projects and 43 are in the clinical trial phase, and 8 are in phase III, which consists of inoculating the vaccine in thousands of volunteers to determine if it really prevents infection.
Despite the now-suspended clinical trial, the project between Oxford University and AstraZeneca is one of the most promising, to which Pfizer and BioNTech, gives Modern and various Chinese projects, namely the CanSinoBIO who has already obtained authorization to administer the vaccine to Chinese military personnel.
See also:
